Company intelligence / Profile preview
Tengion, Inc.
East Norriton, Pennsylvania, United Statesen.wikipedia.org ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Tengion developed regenerative medicine therapies using autologous cells to create functional tissues/organs. Its lead programs included the Neo-Kidney Augment for advanced CKD and the Neo-Urinary Conduit for bladder cancer patients needing urinary diversion. The company entered bankruptcy in 2014 and began liquidating assets; no recent clinical results are available post-liquidation.
- Therapeutic areas
- OncologyNephrology
- Modalities
- Autologous cell therapy (using a patient’s own cells to create neo-organs or neo-tissues)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Tengion, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tengion, Inc..